CRISPR Restriction Upon Termination. Upon termination of this Agreement by Bayer pursuant to Section 16.1(b), 16.1(c) or 16.1(h) becoming effective and for […***…] thereafter, CRISPR shall, and shall procure that its Affiliates will, not, directly or with or through a Third Party, out-license or sell any Pre-IND Products to any Third Party; provided, that in no event shall the out-license or sale of a […***…] be considered a breach of this Section 3.6(d).
Appears in 3 contracts
Sources: Joint Venture Agreement, Joint Venture Agreement (CRISPR Therapeutics AG), Joint Venture Agreement (CRISPR Therapeutics AG)